Larry Dumont
Concepts (326)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Blood Preservation | 43 | 2023 | 311 | 10.520 |
Why?
| Blood Platelets | 28 | 2023 | 369 | 8.270 |
Why?
| Erythrocytes | 24 | 2022 | 641 | 4.080 |
Why?
| Platelet Transfusion | 17 | 2023 | 68 | 3.990 |
Why?
| Blood Donors | 13 | 2021 | 109 | 3.460 |
Why?
| Cryopreservation | 11 | 2023 | 99 | 3.390 |
Why?
| Plateletpheresis | 8 | 2022 | 28 | 1.950 |
Why?
| Antibodies, Viral | 8 | 2023 | 542 | 1.700 |
Why?
| Dimethyl Sulfoxide | 3 | 2023 | 45 | 1.390 |
Why?
| Platelet-Rich Plasma | 2 | 2023 | 29 | 1.300 |
Why?
| Plasma | 6 | 2014 | 224 | 1.250 |
Why?
| Antibodies, Neutralizing | 7 | 2023 | 228 | 1.210 |
Why?
| Pharmaceutical Solutions | 4 | 2014 | 14 | 1.200 |
Why?
| Mannitol | 4 | 2014 | 34 | 1.120 |
Why?
| Membrane Lipids | 3 | 2020 | 88 | 1.080 |
Why?
| Sodium Chloride | 4 | 2014 | 144 | 1.050 |
Why?
| Glucose | 8 | 2017 | 954 | 1.050 |
Why?
| ABO Blood-Group System | 5 | 2020 | 35 | 1.020 |
Why?
| Blood Component Removal | 5 | 2022 | 34 | 0.990 |
Why?
| Adenine | 4 | 2014 | 223 | 0.980 |
Why?
| Metabolome | 4 | 2020 | 296 | 0.930 |
Why?
| Leukocyte Reduction Procedures | 7 | 2020 | 28 | 0.870 |
Why?
| Erythrocyte Transfusion | 9 | 2021 | 210 | 0.860 |
Why?
| Glycolysis | 5 | 2021 | 224 | 0.810 |
Why?
| Cytoskeleton | 1 | 2022 | 181 | 0.770 |
Why?
| Adenosine Triphosphate | 6 | 2015 | 439 | 0.750 |
Why?
| Humans | 85 | 2023 | 119032 | 0.730 |
Why?
| Time Factors | 19 | 2023 | 6414 | 0.710 |
Why?
| Solutions | 4 | 2014 | 156 | 0.670 |
Why?
| Hemostasis | 3 | 2021 | 70 | 0.660 |
Why?
| Glutathione | 2 | 2017 | 324 | 0.650 |
Why?
| Cold Temperature | 3 | 2020 | 132 | 0.640 |
Why?
| Erythrocyte Membrane | 2 | 2020 | 52 | 0.630 |
Why?
| Carrier Proteins | 1 | 2022 | 726 | 0.630 |
Why?
| Blood Grouping and Crossmatching | 3 | 2016 | 16 | 0.600 |
Why?
| Immunization, Passive | 9 | 2022 | 81 | 0.600 |
Why?
| Metabolomics | 5 | 2021 | 550 | 0.560 |
Why?
| Hydrogen-Ion Concentration | 8 | 2015 | 536 | 0.560 |
Why?
| Blood Group Incompatibility | 2 | 2012 | 15 | 0.540 |
Why?
| Dexamethasone | 1 | 2017 | 320 | 0.530 |
Why?
| Cell-Derived Microparticles | 2 | 2018 | 62 | 0.500 |
Why?
| Phosphatidylserines | 2 | 2014 | 91 | 0.500 |
Why?
| Drug Delivery Systems | 1 | 2017 | 306 | 0.500 |
Why?
| Cell Survival | 9 | 2017 | 1047 | 0.500 |
Why?
| Blood Safety | 3 | 2016 | 10 | 0.470 |
Why?
| Carbon Dioxide | 1 | 2015 | 230 | 0.470 |
Why?
| Erythrocyte Aggregation | 1 | 2012 | 3 | 0.450 |
Why?
| Oxidative Stress | 5 | 2020 | 1179 | 0.440 |
Why?
| Transfusion Reaction | 3 | 2022 | 79 | 0.440 |
Why?
| Citrates | 4 | 2017 | 48 | 0.430 |
Why?
| Blood Proteins | 1 | 2014 | 248 | 0.430 |
Why?
| Dicarboxylic Acids | 1 | 2011 | 6 | 0.420 |
Why?
| Polyvinyl Chloride | 1 | 2011 | 5 | 0.420 |
Why?
| Diethylhexyl Phthalate | 1 | 2011 | 9 | 0.420 |
Why?
| Bacteriological Techniques | 2 | 2013 | 66 | 0.410 |
Why?
| United States Food and Drug Administration | 3 | 2016 | 175 | 0.410 |
Why?
| Cyclohexanecarboxylic Acids | 1 | 2011 | 23 | 0.410 |
Why?
| Randomized Controlled Trials as Topic | 4 | 2023 | 1244 | 0.410 |
Why?
| Catheterization, Peripheral | 1 | 2012 | 107 | 0.400 |
Why?
| Energy Metabolism | 2 | 2021 | 767 | 0.400 |
Why?
| Urinary Tract Infections | 1 | 2012 | 136 | 0.390 |
Why?
| Rejuvenation | 1 | 2011 | 14 | 0.390 |
Why?
| Minerals | 1 | 2011 | 39 | 0.390 |
Why?
| Bacteremia | 1 | 2012 | 161 | 0.380 |
Why?
| Evidence-Based Practice | 1 | 2012 | 193 | 0.380 |
Why?
| Hematopoietic Stem Cell Transplantation | 2 | 2022 | 540 | 0.380 |
Why?
| Platelet Aggregation | 3 | 2022 | 97 | 0.380 |
Why?
| Interferon Type I | 2 | 2021 | 129 | 0.370 |
Why?
| Staphylococcus epidermidis | 1 | 2010 | 70 | 0.370 |
Why?
| Oxygen | 3 | 2015 | 857 | 0.360 |
Why?
| Testosterone | 3 | 2022 | 351 | 0.340 |
Why?
| Anaerobiosis | 4 | 2015 | 50 | 0.340 |
Why?
| Leukocytes | 2 | 2023 | 290 | 0.330 |
Why?
| Thrombocytopenia | 2 | 2022 | 185 | 0.330 |
Why?
| Hemostatics | 2 | 2021 | 50 | 0.330 |
Why?
| Citric Acid | 3 | 2012 | 34 | 0.310 |
Why?
| Bacteria | 2 | 2013 | 757 | 0.300 |
Why?
| Seroepidemiologic Studies | 3 | 2021 | 146 | 0.290 |
Why?
| Leukapheresis | 1 | 2006 | 27 | 0.280 |
Why?
| In Vitro Techniques | 4 | 2021 | 1096 | 0.280 |
Why?
| Staphylococcal Infections | 1 | 2010 | 346 | 0.280 |
Why?
| Hemolysis | 6 | 2020 | 174 | 0.280 |
Why?
| Blood Banks | 4 | 2020 | 43 | 0.280 |
Why?
| Specimen Handling | 1 | 2007 | 165 | 0.280 |
Why?
| Blood Transfusion | 4 | 2016 | 306 | 0.270 |
Why?
| Photopheresis | 2 | 2018 | 9 | 0.270 |
Why?
| Anticoagulants | 4 | 2014 | 559 | 0.270 |
Why?
| Adenosine Diphosphate | 2 | 2022 | 88 | 0.270 |
Why?
| Temperature | 3 | 2014 | 622 | 0.270 |
Why?
| Blood Coagulation Tests | 2 | 2015 | 58 | 0.260 |
Why?
| Serologic Tests | 2 | 2022 | 52 | 0.250 |
Why?
| Platelet Count | 4 | 2020 | 83 | 0.250 |
Why?
| Leukocytes, Mononuclear | 2 | 2023 | 509 | 0.240 |
Why?
| 2,3-Diphosphoglycerate | 2 | 2015 | 29 | 0.240 |
Why?
| Autoantibodies | 2 | 2021 | 1335 | 0.230 |
Why?
| Hemoglobins | 4 | 2022 | 326 | 0.230 |
Why?
| Male | 23 | 2022 | 57818 | 0.230 |
Why?
| Adult | 16 | 2023 | 31525 | 0.230 |
Why?
| Hormone Replacement Therapy | 2 | 2021 | 80 | 0.220 |
Why?
| Xenon | 1 | 2022 | 6 | 0.220 |
Why?
| Neuroacanthocytosis | 1 | 2022 | 3 | 0.220 |
Why?
| Furocoumarins | 1 | 2022 | 8 | 0.220 |
Why?
| Refrigeration | 1 | 2022 | 11 | 0.220 |
Why?
| Platelet Function Tests | 1 | 2022 | 25 | 0.220 |
Why?
| Flow Cytometry | 1 | 2006 | 1085 | 0.220 |
Why?
| HMGB1 Protein | 1 | 2022 | 49 | 0.220 |
Why?
| Granulomatous Disease, Chronic | 1 | 2022 | 61 | 0.210 |
Why?
| Hospital Distribution Systems | 1 | 2021 | 1 | 0.210 |
Why?
| Compassionate Use Trials | 1 | 2021 | 8 | 0.210 |
Why?
| Aged | 12 | 2021 | 19661 | 0.200 |
Why?
| Adolescent | 8 | 2021 | 18483 | 0.200 |
Why?
| Middle Aged | 13 | 2021 | 27627 | 0.200 |
Why?
| Female | 18 | 2022 | 61588 | 0.200 |
Why?
| Bone Marrow Transplantation | 1 | 2022 | 244 | 0.190 |
Why?
| Healthy Volunteers | 2 | 2021 | 201 | 0.190 |
Why?
| Feasibility Studies | 1 | 2023 | 749 | 0.190 |
Why?
| Blood Transfusion, Autologous | 1 | 2020 | 22 | 0.190 |
Why?
| Organ Preservation Solutions | 2 | 2012 | 44 | 0.190 |
Why?
| Nonprescription Drugs | 1 | 2021 | 67 | 0.180 |
Why?
| Taurine | 1 | 2020 | 46 | 0.180 |
Why?
| Health Services Needs and Demand | 1 | 2021 | 254 | 0.180 |
Why?
| Antibodies, Monoclonal | 2 | 2016 | 1285 | 0.180 |
Why?
| Oxidation-Reduction | 3 | 2021 | 940 | 0.170 |
Why?
| Cooperative Behavior | 3 | 2012 | 408 | 0.170 |
Why?
| Prescription Drugs | 1 | 2021 | 113 | 0.170 |
Why?
| Cryoprotective Agents | 2 | 2018 | 12 | 0.170 |
Why?
| Extracorporeal Membrane Oxygenation | 1 | 2021 | 244 | 0.170 |
Why?
| Cigarette Smoking | 1 | 2020 | 85 | 0.170 |
Why?
| Asparagine | 1 | 2018 | 30 | 0.170 |
Why?
| Aged, 80 and over | 5 | 2021 | 6562 | 0.170 |
Why?
| Freezing | 1 | 2018 | 87 | 0.170 |
Why?
| Aspartic Acid | 1 | 2018 | 86 | 0.160 |
Why?
| Product Packaging | 2 | 2011 | 3 | 0.160 |
Why?
| Blood Buffy Coat | 1 | 2018 | 6 | 0.160 |
Why?
| Host-Pathogen Interactions | 1 | 2021 | 300 | 0.160 |
Why?
| Buffers | 2 | 2014 | 56 | 0.160 |
Why?
| Lymphoma, T-Cell, Cutaneous | 1 | 2018 | 41 | 0.160 |
Why?
| Nicotine | 1 | 2020 | 276 | 0.150 |
Why?
| Chromatography, Liquid | 2 | 2021 | 355 | 0.150 |
Why?
| Immunoglobulin G | 1 | 2021 | 788 | 0.150 |
Why?
| Pentose Phosphate Pathway | 1 | 2017 | 44 | 0.150 |
Why?
| Radioisotopes | 2 | 2008 | 34 | 0.150 |
Why?
| Cardiac Surgical Procedures | 1 | 2021 | 461 | 0.150 |
Why?
| Young Adult | 8 | 2021 | 10799 | 0.150 |
Why?
| Dithiothreitol | 1 | 2016 | 19 | 0.150 |
Why?
| Tandem Mass Spectrometry | 2 | 2021 | 421 | 0.140 |
Why?
| Histocompatibility Testing | 1 | 2016 | 123 | 0.140 |
Why?
| Protein Processing, Post-Translational | 1 | 2018 | 408 | 0.140 |
Why?
| Government Regulation | 1 | 2016 | 47 | 0.140 |
Why?
| Severity of Illness Index | 2 | 2021 | 2674 | 0.140 |
Why?
| Transfusion Medicine | 1 | 2015 | 10 | 0.140 |
Why?
| Platelet Adhesiveness | 1 | 2015 | 15 | 0.140 |
Why?
| Cross-Over Studies | 3 | 2012 | 456 | 0.140 |
Why?
| Heart-Assist Devices | 1 | 2021 | 485 | 0.130 |
Why?
| Guidelines as Topic | 2 | 2020 | 262 | 0.130 |
Why?
| United States | 8 | 2021 | 12557 | 0.130 |
Why?
| False Positive Reactions | 2 | 2016 | 115 | 0.130 |
Why?
| Monocytes | 1 | 2018 | 513 | 0.130 |
Why?
| Therapeutic Equivalency | 1 | 2014 | 18 | 0.130 |
Why?
| Metabolic Networks and Pathways | 1 | 2016 | 176 | 0.130 |
Why?
| Gases | 1 | 2014 | 46 | 0.130 |
Why?
| Blood Coagulation Factors | 1 | 2014 | 43 | 0.120 |
Why?
| Hematocrit | 1 | 2014 | 91 | 0.120 |
Why?
| Osmolar Concentration | 1 | 2014 | 185 | 0.120 |
Why?
| Hemorrhage | 1 | 2018 | 623 | 0.120 |
Why?
| Disease Progression | 1 | 2021 | 2490 | 0.120 |
Why?
| False Negative Reactions | 2 | 2011 | 57 | 0.120 |
Why?
| Blood Coagulation | 1 | 2015 | 219 | 0.120 |
Why?
| Colony Count, Microbial | 2 | 2011 | 120 | 0.120 |
Why?
| Registries | 1 | 2021 | 1810 | 0.120 |
Why?
| Gas Chromatography-Mass Spectrometry | 1 | 2014 | 135 | 0.120 |
Why?
| Hematologic Neoplasms | 2 | 2018 | 133 | 0.110 |
Why?
| Vaccination | 1 | 2021 | 1223 | 0.110 |
Why?
| P-Selectin | 1 | 2012 | 26 | 0.110 |
Why?
| Phosphoric Acids | 1 | 2012 | 15 | 0.110 |
Why?
| Single-Blind Method | 3 | 2021 | 269 | 0.110 |
Why?
| Microscopy, Electron, Transmission | 1 | 2012 | 140 | 0.100 |
Why?
| Delphi Technique | 1 | 2012 | 164 | 0.100 |
Why?
| Checklist | 1 | 2012 | 81 | 0.100 |
Why?
| Nitrogen Mustard Compounds | 1 | 2011 | 6 | 0.100 |
Why?
| Bacteria, Aerobic | 1 | 2011 | 7 | 0.100 |
Why?
| Acridines | 1 | 2011 | 7 | 0.100 |
Why?
| Heparin | 1 | 2012 | 230 | 0.100 |
Why?
| Bacteria, Anaerobic | 1 | 2011 | 19 | 0.100 |
Why?
| Klebsiella oxytoca | 1 | 2010 | 2 | 0.100 |
Why?
| Immunity, Humoral | 2 | 2023 | 117 | 0.100 |
Why?
| Viridans Streptococci | 1 | 2010 | 4 | 0.100 |
Why?
| Preservatives, Pharmaceutical | 1 | 2011 | 24 | 0.100 |
Why?
| Serratia Infections | 1 | 2010 | 6 | 0.100 |
Why?
| Serratia marcescens | 1 | 2010 | 12 | 0.100 |
Why?
| Klebsiella Infections | 1 | 2010 | 23 | 0.100 |
Why?
| Adaptive Immunity | 2 | 2023 | 161 | 0.100 |
Why?
| Obesity | 2 | 2020 | 2751 | 0.090 |
Why?
| Sensitivity and Specificity | 2 | 2022 | 1795 | 0.090 |
Why?
| Graft vs Host Disease | 1 | 2012 | 216 | 0.090 |
Why?
| Mice | 5 | 2021 | 15528 | 0.090 |
Why?
| Kinetics | 1 | 2014 | 1625 | 0.090 |
Why?
| Consensus | 1 | 2012 | 534 | 0.090 |
Why?
| Erythrocyte Count | 2 | 2007 | 19 | 0.090 |
Why?
| Escherichia coli Infections | 1 | 2010 | 105 | 0.090 |
Why?
| Cell Membrane | 1 | 2014 | 710 | 0.090 |
Why?
| Lipids | 1 | 2014 | 608 | 0.090 |
Why?
| Drug Combinations | 1 | 2011 | 291 | 0.090 |
Why?
| Regression Analysis | 1 | 2012 | 984 | 0.090 |
Why?
| Biopsy, Fine-Needle | 1 | 2009 | 69 | 0.090 |
Why?
| Treatment Outcome | 5 | 2022 | 9346 | 0.090 |
Why?
| Thyroid Nodule | 1 | 2009 | 38 | 0.090 |
Why?
| Thrombosis | 1 | 2012 | 309 | 0.090 |
Why?
| Analysis of Variance | 1 | 2012 | 1295 | 0.090 |
Why?
| Leukocyte Count | 2 | 2007 | 305 | 0.090 |
Why?
| Mice, Inbred C57BL | 2 | 2021 | 4914 | 0.090 |
Why?
| Genetic Heterogeneity | 1 | 2009 | 56 | 0.080 |
Why?
| Publishing | 1 | 2010 | 131 | 0.080 |
Why?
| Safety Management | 1 | 2009 | 109 | 0.080 |
Why?
| Streptococcal Infections | 1 | 2010 | 141 | 0.080 |
Why?
| Proteome | 1 | 2012 | 353 | 0.080 |
Why?
| Animals | 6 | 2022 | 33399 | 0.080 |
Why?
| Transportation | 1 | 2007 | 42 | 0.080 |
Why?
| Ultraviolet Rays | 2 | 2022 | 381 | 0.080 |
Why?
| Staphylococcus aureus | 1 | 2010 | 394 | 0.070 |
Why?
| Escherichia coli | 1 | 2010 | 758 | 0.070 |
Why?
| Cell Separation | 1 | 2007 | 296 | 0.070 |
Why?
| Research Design | 1 | 2012 | 969 | 0.070 |
Why?
| Risk Assessment | 2 | 2012 | 3057 | 0.070 |
Why?
| Survival Analysis | 1 | 2009 | 1267 | 0.070 |
Why?
| Pregnancy | 1 | 2017 | 5694 | 0.060 |
Why?
| Practice Guidelines as Topic | 1 | 2012 | 1440 | 0.060 |
Why?
| Prevalence | 2 | 2021 | 2326 | 0.060 |
Why?
| Genotype | 1 | 2009 | 1882 | 0.060 |
Why?
| Hospitalization | 2 | 2023 | 1785 | 0.060 |
Why?
| Retrospective Studies | 4 | 2020 | 12990 | 0.060 |
Why?
| Neutralization Tests | 1 | 2023 | 66 | 0.060 |
Why?
| Clinical Trials as Topic | 1 | 2008 | 968 | 0.060 |
Why?
| Quality Control | 2 | 2016 | 159 | 0.060 |
Why?
| Blood Gas Analysis | 1 | 2003 | 69 | 0.060 |
Why?
| Prospective Studies | 3 | 2022 | 6477 | 0.060 |
Why?
| CD40 Ligand | 1 | 2022 | 46 | 0.060 |
Why?
| Platelet Activation | 1 | 2003 | 70 | 0.050 |
Why?
| Spike Glycoprotein, Coronavirus | 1 | 2023 | 94 | 0.050 |
Why?
| Masculinity | 1 | 2021 | 8 | 0.050 |
Why?
| Glycerol | 1 | 2022 | 88 | 0.050 |
Why?
| Macaca mulatta | 1 | 2022 | 153 | 0.050 |
Why?
| Thrombin | 1 | 2022 | 143 | 0.050 |
Why?
| Convalescence | 1 | 2021 | 15 | 0.050 |
Why?
| Ranitidine | 1 | 2021 | 13 | 0.050 |
Why?
| Medically Underserved Area | 1 | 2021 | 87 | 0.050 |
Why?
| Public Health Surveillance | 1 | 2021 | 58 | 0.050 |
Why?
| Phosphotransferases (Alcohol Group Acceptor) | 1 | 2021 | 42 | 0.050 |
Why?
| Hematologic Tests | 1 | 2020 | 24 | 0.050 |
Why?
| Osmotic Pressure | 1 | 2020 | 32 | 0.050 |
Why?
| Software | 1 | 2005 | 613 | 0.050 |
Why?
| Ferritins | 1 | 2020 | 61 | 0.050 |
Why?
| Signal Transduction | 1 | 2014 | 4713 | 0.050 |
Why?
| Coronavirus | 1 | 2021 | 41 | 0.050 |
Why?
| Infusions, Intravenous | 1 | 2021 | 380 | 0.050 |
Why?
| Treatment Failure | 1 | 2021 | 341 | 0.050 |
Why?
| Outpatients | 1 | 2023 | 325 | 0.050 |
Why?
| Oxygen Consumption | 1 | 2003 | 586 | 0.050 |
Why?
| Polycythemia | 1 | 2020 | 26 | 0.050 |
Why?
| Hypogonadism | 1 | 2020 | 77 | 0.040 |
Why?
| High-Throughput Screening Assays | 1 | 2021 | 122 | 0.040 |
Why?
| Estradiol | 1 | 2022 | 476 | 0.040 |
Why?
| Platelet Glycoprotein GPIb-IX Complex | 1 | 2018 | 3 | 0.040 |
Why?
| Mice, Inbred NOD | 1 | 2020 | 574 | 0.040 |
Why?
| Tissue Donors | 1 | 2021 | 336 | 0.040 |
Why?
| Developing Countries | 1 | 2020 | 255 | 0.040 |
Why?
| RNA, Viral | 1 | 2022 | 572 | 0.040 |
Why?
| Child | 3 | 2022 | 19137 | 0.040 |
Why?
| Patient Safety | 1 | 2021 | 281 | 0.040 |
Why?
| Methoxsalen | 1 | 2018 | 4 | 0.040 |
Why?
| Phytohemagglutinins | 1 | 2018 | 27 | 0.040 |
Why?
| Annexin A5 | 1 | 2018 | 24 | 0.040 |
Why?
| Health Care Surveys | 1 | 2020 | 546 | 0.040 |
Why?
| Child, Preschool | 2 | 2022 | 9493 | 0.040 |
Why?
| Methylation | 1 | 2018 | 204 | 0.040 |
Why?
| Inpatients | 1 | 2021 | 389 | 0.040 |
Why?
| Machine Learning | 1 | 2021 | 331 | 0.040 |
Why?
| Thrombelastography | 1 | 2018 | 192 | 0.040 |
Why?
| Methods | 1 | 2016 | 67 | 0.040 |
Why?
| ADP-ribosyl Cyclase 1 | 1 | 2016 | 36 | 0.040 |
Why?
| Antiviral Agents | 1 | 2022 | 654 | 0.040 |
Why?
| Cross Reactions | 1 | 2016 | 116 | 0.040 |
Why?
| Logistic Models | 1 | 2021 | 1901 | 0.030 |
Why?
| Erythrocyte Deformability | 1 | 2015 | 12 | 0.030 |
Why?
| Hemorheology | 1 | 2015 | 20 | 0.030 |
Why?
| Socioeconomic Factors | 1 | 2020 | 1129 | 0.030 |
Why?
| Blotting, Western | 1 | 2018 | 1195 | 0.030 |
Why?
| Biochemistry | 1 | 2015 | 40 | 0.030 |
Why?
| Immunoglobulins, Intravenous | 1 | 2016 | 128 | 0.030 |
Why?
| Perfusion | 1 | 2015 | 153 | 0.030 |
Why?
| Mice, Inbred Strains | 1 | 2016 | 405 | 0.030 |
Why?
| Nitric Oxide | 1 | 2020 | 893 | 0.030 |
Why?
| Chromium Radioisotopes | 1 | 2014 | 3 | 0.030 |
Why?
| Species Specificity | 1 | 2016 | 565 | 0.030 |
Why?
| Mice, Knockout | 1 | 2021 | 2680 | 0.030 |
Why?
| Antibodies | 1 | 2016 | 392 | 0.030 |
Why?
| Bacterial Infections | 1 | 2016 | 227 | 0.030 |
Why?
| Genetic Association Studies | 1 | 2016 | 371 | 0.030 |
Why?
| Pandemics | 1 | 2021 | 1355 | 0.030 |
Why?
| Models, Biological | 1 | 2021 | 1715 | 0.030 |
Why?
| Models, Theoretical | 2 | 2009 | 556 | 0.030 |
Why?
| Body Mass Index | 1 | 2020 | 2092 | 0.030 |
Why?
| Proteomics | 1 | 2018 | 876 | 0.030 |
Why?
| Case-Control Studies | 1 | 2020 | 3173 | 0.030 |
Why?
| Electrophoresis, Gel, Two-Dimensional | 1 | 2012 | 106 | 0.030 |
Why?
| Antioxidants | 1 | 2016 | 564 | 0.030 |
Why?
| Hospitals | 1 | 2016 | 601 | 0.020 |
Why?
| Biomarkers | 1 | 2021 | 3590 | 0.020 |
Why?
| Emergency Service, Hospital | 1 | 2021 | 1864 | 0.020 |
Why?
| Cell Proliferation | 1 | 2018 | 2275 | 0.020 |
Why?
| Cells, Cultured | 1 | 2018 | 4081 | 0.020 |
Why?
| Drug Therapy, Combination | 1 | 2012 | 965 | 0.020 |
Why?
| Diphosphoglyceric Acids | 1 | 2008 | 3 | 0.020 |
Why?
| Alkalies | 1 | 2008 | 8 | 0.020 |
Why?
| Aerobiosis | 1 | 2008 | 21 | 0.020 |
Why?
| Apoptosis | 1 | 2018 | 2484 | 0.020 |
Why?
| Risk Factors | 1 | 2021 | 9003 | 0.020 |
Why?
| Automation | 1 | 2007 | 77 | 0.020 |
Why?
| Odds Ratio | 1 | 2009 | 996 | 0.020 |
Why?
| Equipment Design | 1 | 2007 | 519 | 0.020 |
Why?
| Acute Lung Injury | 1 | 2009 | 310 | 0.020 |
Why?
| Evaluation Studies as Topic | 1 | 2005 | 182 | 0.020 |
Why?
| Computer Simulation | 1 | 2009 | 922 | 0.020 |
Why?
| Pilot Projects | 1 | 2008 | 1420 | 0.010 |
Why?
| Sepsis | 1 | 2009 | 531 | 0.010 |
Why?
| Cohort Studies | 1 | 2009 | 5117 | 0.010 |
Why?
|
|
Dumont's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|